Investor Presentaiton

Cardiovascular milvexian Camzyos MYK-224 Milvexian: Opportunity to expand anticoagulation beyond FXa to benefit millions of patients Opportunity to address multiple thrombotic conditions of high unmet need Target profile: Efficacy comparable or better to FXa with better bleeding profile ~7.5M patients² in U.S. with thrombotic diseases need treatment Anti-platelets • SSP Factor Xa ¡ milvexian · AF • ACS ✓ Robust phase 2 program has demonstrated a differentiated anticoagulant profile LIBREXIA program is the largest and most comprehensive phase 3 registrational program ongoing (SSP, ACS & AF) U.S. FDA granted Fast Track Designation to all 3 indications ongoing in Phase 3 studies Ill Bristol Myers Squibb™ 1. Current standard of care for indication(s); 2. Decision Resource Group, BMS Internal Analysis Not for Product Promotional Use 113

View entire presentation